| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $44,002 | 2 | 100 |
Sells | $0 | 0 | 0 |
| Charles Faith L. | director | 1 | $34,002 | 0 | $0 | $34,002 |
| Fisher Michal | director | 1 | $10,000 | 0 | $0 | $10,000 |
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing …
Over the last 12 months, insiders at CNS Pharmaceuticals, Inc. have bought $44,002 and sold $0 worth of CNS Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at CNS Pharmaceuticals, Inc. have bought $53,226 and sold $133,114 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Charles Faith L. (director) — $34,002. Fisher Michal (director) — $10,000.
The last purchase of 7,100 shares for transaction amount of $34,002 was made by Charles Faith L. (director) on 2026‑05‑18.
| 2026-05-18 | Charles Faith L. | director | 7,100 1.2564% | $4.79 | $34,002 | +9.34% | ||
| 2026-05-18 | Fisher Michal | director | 2,000 0.3695% | $5.00 | $10,000 | +9.34% | ||
| 2024-02-01 | Climaco John M | Chief Executive Officer | 166,666 3.2195% | $0.30 | $50,000 | -97.86% | ||
| 2024-02-01 | Downs Christopher | Chief Financial Officer | 66,666 1.2878% | $0.30 | $20,000 | -97.86% | ||
| 2024-02-01 | Gumulka Jerzy | director | 33,333 0.6439% | $0.30 | $10,000 | -97.86% | ||
| 2024-02-01 | Evans Carl Anthony | director | 33,333 0.6439% | $0.30 | $10,000 | -97.86% | ||
| 2023-08-22 | Downs Christopher | Chief Financial Officer | 27,000 0.4674% | $1.27 | $34,177 | -80.93% | ||
| 2023-08-16 | Climaco John M | Chief Executive Officer | 2,750 0.0656% | $1.80 | $4,945 | -80.23% | ||
| 2023-04-19 | Gumulka Jerzy | director | 2,500 0.1259% | $1.70 | $4,250 | -9.60% | ||
| 2023-04-17 | Downs Christopher | Chief Financial Officer | 3,100 0.1892% | $3.20 | $9,920 | -41.09% | ||
| 2023-04-12 | Climaco John M | Chief Executive Officer | 15,000 0.8017% | $0.69 | $10,409 | +139.35% | ||
| 2023-04-10 | Gumulka Jerzy | director | 7,173 0.3716% | $0.74 | $5,308 | +117.57% | ||
| 2023-03-28 | Sale | Priebe Waldemar | 10 percent owner | 10,000 0.551% | $1.04 | $10,400 | +64.65% | |
| 2023-03-27 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2623% | $1.09 | $5,450 | +49.54% | |
| 2023-03-24 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2485% | $1.08 | $5,400 | +45.61% | |
| 2023-03-23 | Sale | Priebe Waldemar | 10 percent owner | 10,000 0.5395% | $1.08 | $10,800 | +56.67% | |
| 2023-03-22 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2552% | $1.08 | $5,400 | +46.85% | |
| 2023-03-21 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2623% | $1.10 | $5,500 | +48.18% | |
| 2023-03-20 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2599% | $1.08 | $5,400 | +49.54% | |
| 2023-03-17 | Sale | Priebe Waldemar | 10 percent owner | 5,000 0.2646% | $1.13 | $5,650 | +48.21% |
| Increased Positions | 5 | +50% | 109,576 | +445.14% |
| Decreased Positions | 3 | -30% | 9,939 | -40.38% |
| New Positions | 4 | New | 108,197 | New |
| Sold Out Positions | 2 | Sold Out | 30 | Sold Out |
| Total Postitions | 12 | +20% | 124,253 | +404.77% |